DEFB136: A Potential Drug Target and Biomarker (G613210)

Target Name: DEFB136

NCBI ID: G613210

DEFB136

DEFB136: A Potential Drug Target and Biomarker

DEFB136 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the DEFB family of proteins, which are known for their role in cell signaling and inflammation. Several studies have suggested that DEFB136 may have potential as a drug target or biomarker, and further research is needed to determine its full potential.

The DEFB136 protein is involved in a number of cellular processes that are important for proper tissue function and development. It has been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of DEFB136 is its role in cell signaling. It is a potent negative regulator of the protein kinase A3 (PKA3), which is involved in a wide range of cellular processes, including cell signaling, DNA replication, and stress response . By regulating the activity of PKA3, DEFB136 helps to maintain the stability and integrity of cellular signaling pathways, and ensures that signals are properly transposed from the cell surface to the inside of the cell.

In addition to its role in cell signaling, DEFB136 has also been shown to play a key role in the regulation of inflammation. It is a potent inhibitor of the nuclear factor-kappa-B (NF-kappa-B), a protein that is involved in the regulation of inflammation and immune responses. By inhibiting the activity of NF-kappa-B, DEFB136 helps to reduce inflammation and promote the immune response.

The potential drug target for DEFB136 is based on its involvement in cell signaling and inflammation. Drugs that can inhibit the activity of DEFB136 or its downstream targets could potentially be used to treat a wide range of diseases, including cancer, neurodegenerative disorders, and autoimmune disorders.

Another potential application of DEFB136 as a drug target is its role in the regulation of cell death. It has been shown to play a key role in the regulation of apoptosis, a process that is involved in the natural death of cells. By promoting apoptosis, DEFB136 helps to remove damaged or dysfunctional cells from the body, which can potentially reduce the risk of disease.

In addition to its potential as a drug target, DEFB136 has also been suggested as a potential biomarker. Its involvement in the regulation of cell signaling and inflammation makes it an attractive candidate for use as a biomarker for a wide range of diseases. For example, DEFB136 has been shown to be elevated in the brains of patients with Alzheimer's disease, a neurodegenerative disorder. Additionally, DEFB136 has been shown to be elevated in the blood of patients with multiple sclerosis, an autoimmune disorder.

While further research is needed to fully understand the potential of DEFB136 as a drug target and biomarker, its involvement in cell signaling and inflammation makes it an intriguing candidate for further study. As research continues to advance, the full potential of DEFB136 as a drug target and biomarker may become increasingly clear.

Protein Name: Defensin Beta 136

Functions: Host defense peptide that exhibits antibacterial and antifungal activity (PubMed:34481960). Exhibits antimicrobial activity against E.coli, S.aureus and C.albicans (in vitro) (PubMed:34481960). Has high lipopolysaccharide (LPS)-binding affinity, and may thereby be involved in immunoregulation through LPS neutralization (PubMed:34481960)

The "DEFB136 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB136 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets